Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Dec 21, 2008; 14(47): 7225-7230
Published online Dec 21, 2008. doi: 10.3748/wjg.14.7225
Published online Dec 21, 2008. doi: 10.3748/wjg.14.7225
Table 2 Univariate analysis of association between sustained virological response (SVR) and influential factors (mean ± SE)
Factor | SVR patients (n = 53) | Non-SVR patients (n = 67) | P |
Parameters before interferon treatment | |||
Age (yr) | 52.5 ± 1.50 | 56.5 ± 1.26 | 0.0481 |
Sex (Male:Female) | 35:18 | 35:32 | 0.1402 |
Body mass index | 23.6 ± 0.48 | 23.8 ± 0.44 | 0.3611 |
Viral load (kirocopies/mL, median) | 1500 | 1800 | 0.1963 |
ALT (IU/L) | 108.4 ± 13.8 | 74.5 ± 7.04 | 0.0478 |
WBC (/μL) | 5227 ± 201 | 4967 ± 186 | 0.2880 |
Hemoglobin (g/dL) | 14.5 ± 0.18 | 14.3 ± 0.16 | 0.2352 |
Platelet (× 103/μL) | 173 ± 7.7 | 155 ± 5.7 | 0.0630 |
Parameters associated with treatment | |||
EVR | 42/51 (82.4%) | 13/59 (22.0%) | < 0.0001 |
Cumulative exposure to peg-IFN | |||
12 wk (≥ 80%/< 80%) | 38/41 (92.7%) | 41/69 (68.3%) | 0.0034 |
Overall (≥ 80%/< 80%) | 35/41 (85.4%) | 29/60 (48.3%) | 0.0001 |
Cumulative exposure to RBV | |||
12 wk (≥ 80%/< 80%) | 41/50 (82%) | 44/63 (69.8%) | 0.1882 |
Overall (≥ 80%/< 80%) | 32/50 (64%) | 25/63 (39.7%) | 0.0138 |
- Citation: Kogure T, Ueno Y, Fukushima K, Nagasaki F, Kondo Y, Inoue J, Matsuda Y, Kakazu E, Yamamoto T, Onodera H, Miyazaki Y, Okamoto H, Akahane T, Kobayashi T, Mano Y, Iwasaki T, Ishii M, Shimosegawa T. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008; 14(47): 7225-7230
- URL: https://www.wjgnet.com/1007-9327/full/v14/i47/7225.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.7225